1-3 of 3
Sapna P. Patel
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma

Kenneth F. Grossmann, Megan Othus, Sapna P. Patel, Ahmad A. Tarhini, Vernon K. Sondak, Michael V. Knopp, Teresa M. Petrella, Thach-Giao Truong, Nikhil I. Khushalani, Justine V. Cohen, Elizabeth I. Buchbinder, Kari Kendra, Pauline Funchain, Karl D. Lewis, Robert M. Conry, Bartosz Chmielowski, Ragini R. Kudchadkar, Douglas B. Johnson, Hongli Li, James Moon, Zeynep Eroglu, Brian Gastman, Magdalena Kovacsovics-Bankowski, Krishna S. Gunturu, Scot W. Ebbinghaus, Sama Ahsan, Nageatte Ibrahim, Elad Sharon, Larissa A. Korde, John M. Kirkwood, Antoni Ribas
Journal: Cancer Discovery
Cancer Discov (2022) 12 (3): 644–653.
https://doi.org/10.1158/2159-8290.CD-21-1141
Published: 08 March 2022
View articletitled, Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma
Open the PDF for Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma in another window
Includes: Supplementary data
Journal Articles

First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study

Ryan J. Sullivan, Jeffrey R. Infante, Filip Janku, Deborah Jean Lee Wong, Jeffrey A. Sosman, Vicki Keedy, Manish R. Patel, Geoffrey I. Shapiro, James W. Mier, Anthony W. Tolcher, Andrea Wang-Gillam, Mario Sznol, Keith Flaherty, Elizabeth Buchbinder, Richard D. Carvajal, Anna M. Varghese, Mario E. Lacouture, Antoni Ribas, Sapna P. Patel, Gary A. DeCrescenzo, Caroline M. Emery, Anna L. Groover, Saurabh Saha, Mary Varterasian, Dean J. Welsch, David M. Hyman, Bob T. Li
Journal: Cancer Discovery
Series: Author Choice
Cancer Discov (2018) 8 (2): 184–195.
https://doi.org/10.1158/2159-8290.CD-17-1119
Published: 04 February 2018
View articletitled, First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study
Open the PDF for First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study in another window
Includes: Supplementary data
Journal Articles

Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade

Pei-Ling Chen, Whijae Roh, Alexandre Reuben, Zachary A. Cooper, Christine N. Spencer, Peter A. Prieto, John P. Miller, Roland L. Bassett, Vancheswaran Gopalakrishnan, Khalida Wani, Mariana Petaccia De Macedo, Jacob L. Austin-Breneman, Hong Jiang, Qing Chang, Sangeetha M. Reddy, Wei-Shen Chen, Michael T. Tetzlaff, Russell J. Broaddus, Michael A. Davies, Jeffrey E. Gershenwald, Lauren Haydu, Alexander J. Lazar, Sapna P. Patel, Patrick Hwu, Wen-Jen Hwu, Adi Diab, Isabella C. Glitza, Scott E. Woodman, Luis M. Vence, Ignacio I. Wistuba, Rodabe N. Amaria, Lawrence N. Kwong, Victor Prieto, R. Eric Davis, Wencai Ma, Willem W. Overwijk, Arlene H. Sharpe, Jianhua Hu, P. Andrew Futreal, Jorge Blando, Padmanee Sharma, James P. Allison, Lynda Chin, Jennifer A. Wargo
Journal: Cancer Discovery
Cancer Discov (2016) 6 (8): 827–837.
https://doi.org/10.1158/2159-8290.CD-15-1545
Published: 01 August 2016
View articletitled, Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade
Open the PDF for Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade in another window
Includes: Supplementary data